Maria-Luisa Maccecchini
CIK: 0001315018
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jan 9, 2026LTRN
Lantern Pharma Inc.
Award(A)DirectStock Option (Right to Buy)
25K shares- - Jan 9, 2026LTRN
Lantern Pharma Inc.
Award(A)DirectStock Option (Right to Buy)
21.2K shares- - Oct 28, 2025ANVS
Annovis Bio, Inc.
Purchase(P)Direct97.6K shares at avg. $2.05$200K - Jun 4, 2025ANVS
Annovis Bio, Inc.
Award(A)Direct46K shares at avg. $3.37$155K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 9, 2026 |  LTRN Lantern Pharma Inc. | Award(A) Stock Option (Right to Buy) | 25,000 | - | - | Direct |
| Jan 9, 2026 | LTRN Lantern Pharma Inc. | Award(A) Stock Option (Right to Buy) | 21,152 | - | - | Direct |
| Oct 28, 2025 |  ANVS Annovis Bio, Inc. | Purchase(P) | 97,561 | $2.05 | $200,000 | Direct |
| Jun 4, 2025 | ANVS Annovis Bio, Inc. | Award(A) | 46,000 | $3.37 | $155,020 | Direct |
1-4 of 4 transactions
About Maccecchini Maria-Luisa
Maccecchini Maria-Luisa (SEC CIK 0001315018) files insider reports with the SEC as Director of Lantern Pharma Inc. (LTRN) and President & CEO of Annovis Bio, Inc. (ANVS).
Signal8 holds 3 ownership filings by Maccecchini Maria-Luisa, all Form 4s, filed between Jun 5, 2025 and Jan 13, 2026. Those filings report 4 transactions, from Jun 4, 2025 to Jan 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Maccecchini Maria-Luisa's filings is in DALLAS, TX.
Recent filings by Maccecchini Maria-Luisa
Other insiders filing for Lantern Pharma Inc. (LTRN)
- Schalop Lee Troy, Director
- KEYSER D JEFFREY, Director
- Chandru Vijay, Director
- Silberstein David S., Director
- Margrave David R., Chief Financial Officer
- Bhatia Kishor G., Chief Scientific Officer